1594P Outcome, mortality and 30-day readmission of pericardial effusion in cancer patients

Abstract

Listen

Translate article

A pericardial effusion (PE) with various inflammatory and non-inflammatory causes can range from an incidental finding to a life-threatening emergency such as a cardiac tamponade. In the literature, little is known about the outcomes of PE in cancer patients. The study's primary objective was to assess whether intervention in PE affects in-hospital mortality and 30-days readmission among cancer patients. A retrospective study of a nationally representative cohort of hospital admissions was conducted from January 1, 2016, to December 31, 2019. Data was collected from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project Nationwide Readmissions Database. All adult patients ≥18 years admitted with primary diagnosis of pericardial effusion in cancer patients were included in the study. We used the International Classification of Diseases, 10th revision, diagnostic codes to identify variable. The type of cancer included in the study were Breast, Lung, pancreatic, bladder, renal, colorectal, lymphoma and acute leukemia. The patients were stratified as PE in cancer patients underwent intervention versus no intervention. A total of 37,430 index hospitalizations for PE in cancer patients were identified for the years 2016-2019 in the NRD with the 27,980 index hospitalizations for PE without intervention, and 9,450 index hospitalizations for PE with intervention. There was no difference in in-hospital mortality for PE with and without intervention (4.5% vs 4.4%; p 0.76). However, PE without intervention had a significantly higher 30-day readmission rate than PE with intervention (31% vs 4.2.0%; p <0.001). The PE with intervention group had higher multi-organ complications including cardiogenic shock (8.6% vs 5.5%; p-value <0.001), Acute Kidney Injury (AKI) (29% vs 24.0%; p-value <0.001), respiratory failure (25% vs 20%, p-value <0.001), pneumonia (15% vs 12.6%, p-value 0.004), atrial fibrillation (27% vs 23.8%, p-value<0.001). Survival rates were not different between patients who received intervention and those who did not, but 30-day readmission rates were significantly higher for patients who did not receive intervention. Cancer patients would benefit from PE intervention.